Portfolio Lab

Syndax Pharmaceuticals Inc

  • Stock
  • Ticker SNDX
  • ISIN US87164F1057
  • Nasdaq

Health care · Pharmaceuticals · USA

$8.72 −4.49%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Syndax Pharmaceuticals Inc since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

SNDXGlobal equities (VT)

$10,000 grew to $8,441. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −75.8% in 12/2018, measured from the peak in 03/2017. It took 38 months to get back to the old peak.

1-year return
−48.9%
5-year return p.a.
−13.3%
10-year return p.a.
−1.7%
Volatility p.a.
66.6%
Largest decline
−75.8%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue7.720384669657383
Operating income-96-84-69-57-63-34-40-42
EBITDA–-84-69-54-60-30-35-36
Net income-94-85-72-61-68-43-49-49
Earnings per share-1.09-0.98-0.83-0.70-0.78-0.48-0.55-0.55
Balance sheet
Total assets725641596552530473704693
Liabilities437426439436465431689710
Equity288215157115654215-17
Cash154154109117135131336136
Cash flow
Operating cash flow-57-95-88-71-69-50-30-27
Free cash flow-57-95-88-71-69-50-30-27

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2020 at +153.3%, weakest 2018 at −49.2%. 5 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
2 Nov 2026−$0.55
4 Aug 2026−$0.55
30 Apr 2026−$0.48
26 Feb 2026−$0.78
3 Nov 2025−$0.70
4 Aug 2025−$0.83
5 May 2025−$0.98
3 Mar 2025−$1.09
5 Nov 2024−$0.98
1 Aug 2024−$0.80
8 May 2024−$0.85
27 Feb 2024−$1.01

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€711m
Market cap in trading currency
$785m
Enterprise value
$708m
P/E
–
P/S
2.71
P/B
–
EV/Sales
2.44
EV/EBITDA
–
Earnings yield
–
FCF yield
-22.6%

Results (last four quarters)

Revenue
$290m
Gross profit
–
EBITDA
−$161m
Net income
−$209m
Earnings per share
−$2.36
Revenue per share
$3.22
Revenue growth
+81.6%
Earnings growth
–

Profitability

Gross margin
–
Operating margin
-61.7%
Net margin
-72.3%
Return on equity
–
Return on assets
-30.2%

Balance sheet and cash flow

Cash
$427m
Cash per share
$4.75
Financial debt
$350m
Debt/equity %
–
Current ratio
4.69
Book value per share
−$0.19
Operating cash flow
−$177m
Free cash flow
−$177m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
–
Ex-dividend date
–

Shares and trading

Shares outstanding
90.0m
Volume
2.18m
Avg. volume 3 months
2.53m
Relative volume
0.8

Price and technicals

Price
$8.72
1 day
−4.5%
52-week high
$25.15
52-week low
$8.56
Distance to 52-week high
−65.3%
Distance to 52-week low
+1.9%
Distance to 50-day line
−38.7%
Distance to 200-day line
−55.1%
RSI (14)
28
Volatility 1M
127.0%

Performance

1 week
−7.7%
1 month
−35.7%
3 months
−55.4%
6 months
−56.3%
YTD
−58.5%
1 year
−47.8%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has SNDX performed since 11/2016?

$10,000 grew to $8,441 by 20 Nov 2026, which is −1.7% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is SNDX?

Volatility was 66.6% per year, measured on monthly returns. The largest decline from a peak was −75.8%, with the low in 12/2018.

How does SNDX compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, SNDX returned −1.7% at 66.6%. The correlation of monthly returns was 0.28; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Syndax Pharmaceuticals Inc (SNDX): Return and risk